401 related articles for article (PubMed ID: 34177947)
1. Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.
Smith CIE; Burger JA
Front Immunol; 2021; 12():689472. PubMed ID: 34177947
[TBL] [Abstract][Full Text] [Related]
2. Noncatalytic Bruton's tyrosine kinase activates PLCγ
Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
[TBL] [Abstract][Full Text] [Related]
3. MCIR1: A patient-derived mantle cell lymphoma line for discovering new treatments for ibrutinib resistance.
Wu X; Nowakowski KE; Abeykoon JP; Manske M; Stenson MJ; Timm MM; Hanson CA; Van Dyke DL; Dasari S; Witzig TE
Eur J Haematol; 2021 Oct; 107(4):458-465. PubMed ID: 34214199
[TBL] [Abstract][Full Text] [Related]
4. Bruton's tyrosine kinase inhibition induces rewiring of proximal and distal B-cell receptor signaling in mice.
Rip J; de Bruijn MJW; Neys SFH; Singh SP; Willar J; van Hulst JAC; Hendriks RW; Corneth OBJ
Eur J Immunol; 2021 Sep; 51(9):2251-2265. PubMed ID: 34323286
[TBL] [Abstract][Full Text] [Related]
5. BTK-independent regulation of calcium signalling downstream of the B-cell receptor in malignant B-cells.
Arthur R; Wathen A; Lemm EA; Stevenson FK; Forconi F; Linley AJ; Steele AJ; Packham G; Valle-Argos B
Cell Signal; 2022 Aug; 96():110358. PubMed ID: 35597428
[TBL] [Abstract][Full Text] [Related]
6. Bruton Tyrosine Kinase Inhibitors: Present and Future.
Burger JA
Cancer J; 2019; 25(6):386-393. PubMed ID: 31764119
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.
Wang E; Mi X; Thompson MC; Montoya S; Notti RQ; Afaghani J; Durham BH; Penson A; Witkowski MT; Lu SX; Bourcier J; Hogg SJ; Erickson C; Cui D; Cho H; Singer M; Totiger TM; Chaudhry S; Geyer M; Alencar A; Linley AJ; Palomba ML; Coombs CC; Park JH; Zelenetz A; Roeker L; Rosendahl M; Tsai DE; Ebata K; Brandhuber B; Hyman DM; Aifantis I; Mato A; Taylor J; Abdel-Wahab O
N Engl J Med; 2022 Feb; 386(8):735-743. PubMed ID: 35196427
[TBL] [Abstract][Full Text] [Related]
8. A novel somatic PLCG2 variant associated with resistance to BTK and SYK inhibition in chronic lymphocytic leukemia.
Raghunathan V; Fan G; Kittai AS; Okada C; Danilov AV; Spurgeon SE
Eur J Haematol; 2021 Feb; 106(2):294-297. PubMed ID: 33089525
[TBL] [Abstract][Full Text] [Related]
9. B-cell receptor signaling as a driver of lymphoma development and evolution.
Niemann CU; Wiestner A
Semin Cancer Biol; 2013 Dec; 23(6):410-21. PubMed ID: 24060900
[TBL] [Abstract][Full Text] [Related]
10. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.
Woyach JA; Furman RR; Liu TM; Ozer HG; Zapatka M; Ruppert AS; Xue L; Li DH; Steggerda SM; Versele M; Dave SS; Zhang J; Yilmaz AS; Jaglowski SM; Blum KA; Lozanski A; Lozanski G; James DF; Barrientos JC; Lichter P; Stilgenbauer S; Buggy JJ; Chang BY; Johnson AJ; Byrd JC
N Engl J Med; 2014 Jun; 370(24):2286-94. PubMed ID: 24869598
[TBL] [Abstract][Full Text] [Related]
11. Targeting BTK in B Cell Malignancies: From Mode of Action to Resistance Mechanisms.
Mouhssine S; Maher N; Matti BF; Alwan AF; Gaidano G
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542207
[TBL] [Abstract][Full Text] [Related]
12. Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies.
Ondrisova L; Mraz M
Front Oncol; 2020 Oct; 10():591577. PubMed ID: 33154951
[TBL] [Abstract][Full Text] [Related]
13. Kinase-deficient BTK mutants confer ibrutinib resistance through activation of the kinase HCK.
Dhami K; Chakraborty A; Gururaja TL; Cheung LW; Sun C; DeAnda F; Huang X
Sci Signal; 2022 May; 15(736):eabg5216. PubMed ID: 35639855
[TBL] [Abstract][Full Text] [Related]
14. A conditional form of Bruton's tyrosine kinase is sufficient to activate multiple downstream signaling pathways via PLC Gamma 2 in B cells.
Tomlinson MG; Woods DB; McMahon M; Wahl MI; Witte ON; Kurosaki T; Bolen JB; Johnston JA
BMC Immunol; 2001; 2():4. PubMed ID: 11410123
[TBL] [Abstract][Full Text] [Related]
15. Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies.
Stephens DM; Byrd JC
Blood; 2021 Sep; 138(13):1099-1109. PubMed ID: 34320163
[TBL] [Abstract][Full Text] [Related]
16. Overcoming Acquired Epigenetic Resistance to BTK Inhibitors.
Shaffer AL; Phelan JD; Wang JQ; Huang D; Wright GW; Kasbekar M; Choi J; Young RM; Webster DE; Yang Y; Zhao H; Yu X; Xu W; Roulland S; Ceribelli M; Zhang X; Wilson KM; Chen L; McKnight C; Klumpp-Thomas C; Thomas CJ; Häupl B; Oellerich T; Rae Z; Kelly MC; Ahn IE; Sun C; Gaglione EM; Wilson WH; Wiestner A; Staudt LM
Blood Cancer Discov; 2021 Nov; 2(6):630-647. PubMed ID: 34778802
[TBL] [Abstract][Full Text] [Related]
17. Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies.
Kapoor I; Li Y; Sharma A; Zhu H; Bodo J; Xu W; Hsi ED; Hill BT; Almasan A
Cell Death Dis; 2019 Dec; 10(12):924. PubMed ID: 31801949
[TBL] [Abstract][Full Text] [Related]
18. Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance.
Naeem A; Utro F; Wang Q; Cha J; Vihinen M; Martindale S; Zhou Y; Ren Y; Tyekucheva S; Kim AS; Fernandes SM; Saksena G; Rhrissorrakrai K; Levovitz C; Danysh BP; Slowik K; Jacobs RA; Davids MS; Lederer JA; Zain R; Smith CIE; Leshchiner I; Parida L; Getz G; Brown JR
Blood Adv; 2023 May; 7(9):1929-1943. PubMed ID: 36287227
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia.
Geethakumari PR; Awan F
Expert Rev Hematol; 2020 Oct; 13(10):1039-1046. PubMed ID: 32869675
[TBL] [Abstract][Full Text] [Related]
20. Cooperative miRNA-dependent PTEN regulation drives resistance to BTK inhibition in B-cell lymphoid malignancies.
Kapoor I; Bodo J; Hill BT; Almasan A
Cell Death Dis; 2021 Nov; 12(11):1061. PubMed ID: 34750354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
